Sinopharm Capital

Investor type Private Equity Firm


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 37
Average round size
The average size of a deal this fund participated in
Portfolio companies 35
Rounds per year 3.70
Lead investments 10
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 3
Key employees Soon

Areas of investment

  • Health Care
  • Biotechnology
  • Medical
  • Pharmaceutical
  • Manufacturing

Sinopharm Capital is the famous VC, which was founded in 2012. The venture was found in Asia in China. The main department of described VC is located in the Shanghai.

Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in 2-6 investment rounds annually. The real fund results show that this VC is 51 percentage points more often commits exit comparing to other companies. The high activity for fund was in 2018.

For fund there is a match between the location of its establishment and the land of its numerous investments - China. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Ansun BioPharma, Dingdang Kuaiyao, HealthCare Biotech. Among the most popular fund investment industries, there are Health Care, Pharmaceutical. The fund has no exact preference in a number of founders of portfolio startups.

The standard case for the fund is to invest in rounds with 2-3 partakers. Despite the Sinopharm Capital, startups are often financed by ZhenFund, Sequoia Capital China, PrairieGold Venture Partners. The meaningful sponsors for the fund in investment in the same round are TF Capital, Lilly Asia Ventures, YuanMing Capital. In the next rounds fund is usually obtained by Lilly Asia Ventures, TF Capital, Qiming Venture Partners.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Sinopharm Capital:
Typical Co-investors
Sinopharm Capital is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Sinopharm Capital:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Arc Capital Development Colorado, Denver, United States
BMNT California, Palo Alto, United States
Cloud Power Capital Austin, Texas, United States
Corriente Advisors Fort Worth, Texas, United States
Da Vinci Capital Castel, Guernsey, Guernsey
Hegemon Group International -
HSBC Bank Oman -
Landmark Partners Connecticut, Simsbury, United States
Latona Associates -
North Coast Technology Investors Ann Arbor, Michigan, United States
Oisix Japan, Shinagawa
POSCO Venture Partners Seoul, Seoul-t'ukpyolsi, South Korea
Sanchez Capital Partners Austin, Texas, United States
Soaring Capital Beijing, Beijing, China
The Galleon Group -
The Norinchukin Bank Chiyoda, Japan
Zen Water Capital -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation


Artificial Intelligence
$10M31 Mar 2022 Pudong, Shandong, China


Health Care
Medical Device
$15M13 Dec 2021 Chongqing, Chongqing, China

Longhui Medical

Health Care
Medical Device
$15M26 Nov 2021 Shanghai, Shanghai, China

Sepax Technologies

$77M15 Nov 2021 Delaware, Ohio, United States

Shanghai Ouyi Biomedical Technology

Health Diagnostics
Life Science
$15M02 Nov 2021 Shanghai, Shanghai, China


28 Sep 2021 Chengdu, Sichuan, China

Yikon Genomics

$38M06 May 2021 Minhang District, China


$46M12 Mar 2021 -

Dingdang Kuaiyao

$154M20 Oct 2020 Dongcheng District, Beijing, China


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Sinopharm Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: